Jason B. Litten
Chief Tech/Sci/R&D Officer at CHIMERIC THERAPEUTICS LIMITED
Jason B. Litten active positions
Companies | Position | Start | End |
---|---|---|---|
CHIMERIC THERAPEUTICS LIMITED | Chief Tech/Sci/R&D Officer | 2022-07-24 | - |
Optera Therapeutics Corp. | Chief Tech/Sci/R&D Officer | - | - |
Career history of Jason B. Litten
Former positions of Jason B. Litten
Companies | Position | Start | End |
---|---|---|---|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 2019-07-31 | 2022-06-05 |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
JUNO THERAPEUTICS INC | Corporate Officer/Principal | - | - |
Training of Jason B. Litten
Emory University | Doctorate Degree |
Cornell University | Undergraduate Degree |
Statistics
International
United States | 7 |
Australia | 2 |
Operational
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
CHIMERIC THERAPEUTICS LIMITED | Health Technology |
Private companies | 4 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Health Technology |
Optera Therapeutics Corp. |
- Stock Market
- Insiders
- Jason B. Litten
- Experience